Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy

• DOI: 10.3389/fonc.2021.640910
• Publication Date: 2021-05-27T04:16:55Z
• Authors: Li Hu; Xingbo Cheng; Zev Binder; Zhibin Han; Yibo Yin; Donald M. O’Rourke; Sida Wang; Yumeng Feng; Changjiang Weng; Anhua Wu; Zhiguo Lin
• Keywords: 0301 basic medicine; PTEN; 03 medical and health sciences; Oncology; pAkt; glioblastoma multiform; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; prognosis; UBE2S; chemo-radiotherapy; RC254-282; 3. Good health

Glioblastoma is the most common and lethal brain cancer globally. Clinically, this has heterogenous molecular clinical characteristics. Studies have shown that UBE2S highly expressed in many cancers. But its expression profile glioma, correlation with outcomes unknown. RNA sequencing data of glioma samples was downloaded from Chinese Glioma Genome Atlas The Cancer Atlas. A total 114 cases tissue (WHO grades II-IV) were used to conduct protein assays. biological characteristics UBE2S, prognostic value analyzed. results showed high associated a higher grade PTEN mutations. In addition, affected degree malignancy development chemo-radiotherapy resistance. It also found be an independent predictor worse survival LGG patients. Furthermore, we identified five ubiquitination sites Akt phosphorylation malignant glioblastoma. revealed negatively correlated 1p19q loss IDH1 mutation; positively epidermal growth factor receptor amplification mutation. This study demonstrates strongly correlates resistance chemo-radiotherapy. crucial biomarker poor prognosis.